Background-Several lines of evidence support a pathophysiological role of immunity in atherosclerosis. Tyrosinenitrated proteins, a footprint of oxygen-and nitrogen-derived oxidants generated by cells of the immune system, are enriched in atheromatous lesions and in circulation of patients with coronary artery disease (CAD). However, the consequences of possible immune reactions triggered by the presence of nitrated proteins in subjects with clinically documented atherosclerosis have not been explored. Methods and Results-Specific immunoglobulins that recognize 3-nitrotyrosine epitopes were identified in human lesions, as well as in circulation of patients with CAD. The levels of circulating immunoglobulins against 3-nitrotyrosine epitopes were quantified in patients with CAD (nϭ374) and subjects without CAD (non-CAD controls, nϭ313). A 10-fold increase in the mean level of circulating immunoglobulins against protein-bound 3-nitrotyrosine was documented in patients with CAD (3.75Ϯ1.8 g antibody Eq/mL plasma versus 0.36Ϯ0.8 g antibody Eq/mL plasma), and was strongly associated with angiographic evidence of significant CAD. Conclusions-The results of this cross-sectional study suggest that posttranslational modification of proteins via nitration within atherosclerotic plaque-laden arteries and in circulation serve as neo-epitopes for the elaboration of immunoglobulins, thereby providing an association between oxidant production and the activation of the immune system in CAD.
Chronic inflammation, oxidative processes, and the activation of the immune system are implicated in the pathogenesis of atherosclerosis. [1] [2] [3] The detection and quantification of tyrosine-nitrated proteins in human and animal models of atherosclerosis has provided one of the mechanistic links between chronic inflammation and oxidative processes in coronary artery disease (CAD). Tyrosine nitration is a covalent posttranslational modification of proteins that arises from the reaction of protein tyrosine residues with nitric oxide-derived oxidants. 4 -6 Using mass spectrometry-based proteomic approaches, site-specific nitration of proteins with pathobiological relevance to CAD have been revealed, 7, 8 whereas quantification of 3-nitrotyrosine in plasma using stable isotope dilution liquid chromatography tandem mass spectrometry demonstrated its association with CAD. 9 Despite the potential utility of 3-nitrotyrosine as a biomarker, at the individual protein level, it remains unclear whether protein nitration is responsible for alterations in cellular function that imparts an increased risk for disease development or unfavorable outcomes. Emerging data implicate tyrosine nitration as an activator of immune responses, including the elaboration of immunoglobulins, and in inflammatory diseases such as acute lung injury, osteoarthritis, rheumatoid arthritis, and systemic lupus erythematosus. 10 -12 Moreover, a possible role of immune modulation by protein nitration can be evoked in other prevalent vascular diseases, such as angiotensin II-induced hypertension in which oxidants, T cells, and infiltrating monocytes contribute to the disease pathogenesis. 13, 14 In this study, we provide clinical data demonstrating that circulating immunoglobulins that recognize protein-bound 3-nitrotyrosine are increased in patient with CAD and are associated with enhanced risk of angiographic evidence of significant CAD.
Materials and Methods

Subjects
Stable subjects undergoing elective diagnostic cardiac evaluation with coronary angiography were recruited prospectively to participate. All blood draws were from fasting subjects, venous sampling into EDTA (lavender top) Vacutainers prior to heparin administration from sequential consenting subjects at the time of cardiac catheterization. Blood was placed immediately either on ice or in a refrigerator, and centrifuged subsequently for 15 minutes at 10 000 g at 4°C. Plasma was maintained between 0°C and 4°C, and aliquots were frozen at Ϫ80°C within 2 hours of blood draw. Subjects who experienced acute coronary syndrome within 30 days of sample collection or had significant end-organ dysfunction were excluded. All subjects included in the current studies were confirmed to be troponin I (Abbott Architect assay) negative. Angiographic evidence of significant CAD was defined by the presence of at least 50% stenosis in one or more major coronary vessel as judged by at least 2 cardiologists blinded to patient identification and history. The demographic data for the subjects are reported in Table 1 . Subjects with no history of CAD, significant angiographic (using Ն50% stenosis as the cutoff) evidence of cardiovascular disease, peripheral artery disease, or other significant end-organ dysfunction were considered non-CAD subjects. The reasons for cardiac catheterization in the study cohort (subjects can have 1 or more reasons) included history of positive or indeterminate stress test (46%), evaluation for possible ischemic causes of symptoms (69%), preoperative evaluation (14%), and history of cardiomyopathy (3%). All study participants gave informed consent, and the study was approved by the Cleveland Clinic Institutional Review Board.
Materials
Free 3-nitrotyrosine and the synthetic octapeptide containing 2 3-nitrotyrosine residues (CGnitroYGGGnitroYG) (CPC Scientific, San Jose, CA) were conjugated to horseradish peroxidase (HRP) following a previously published 1-step procedure. 10 Affinitypurified polyclonal antinitrotyrosine antibodies were generated and characterized extensively, 8, 15, 16 and used as reference immunoglobulin. Synthetic peptides comprising amino acids 213 to 219 of human apolipoprotein A-I sequence ( 213 LAEYHAK 219 ) with either tyrosine in position 216 or 3-nitrotyrosine ( 213 LAEnitroYHAK 219 ) were used for ligand competition. Human fibrinogen (America Diagnostica, Stamford, CT), fibronectin, and ceruloplasmin were nitrated by adding 3 consecutive bolus additions of peroxynitrite (final concentration, 100 mol/L) in 0.1 mol/L phosphate buffer containing 100 mol/L diethylene triamine pentaacetic acid and 25 mmol/L bicarbonate, pH 7.2. These proteins were nitrated chemically and used to screen for the circulating immunoglobulin isotype.
Immunohistochemistry
To probe for tyrosine-nitrated proteins, sections from human carotid atheromatous lesions were fixed in cold methanol-acetone solution for 20 minutes at Ϫ20°C. Staining for tyrosine-nitrated proteins was performed using rabbit polyclonal affinity-purified antinitrotyrosine antibodies (7 g/mL) raised against the synthetic peptide described previously. 15, 16 A goat antirabbit secondary antibody conjugated to HRP (Biorad, Hercules, CA) was used for signal detection. As control for the specificity of the antibody binding, the anti-3nitrotyrosine antibody was preincubated with 250 mol/L 3-nitrotyrosine octapeptide or with 250 mol/L of the corresponding tyrosine octapeptide for 1 hour at room temperature. Other control experiments included preincubation with 2.5 mmol/L free 3-nitrotyrosine, reduction of tissue nitrotyrosine to aminotyrosine using 0.5 mol/L dithionite in 0.1 N sodium hydroxide for 20 minutes at room temperature, as well as omission of the primary antibody. Oil Values expressed in meanϮstandard deviation or median (interquartile range). LDL indicates low-density lipoprotein; HDL, high-density lipoprotein; WBC/hpf, white blood cells per high power field; and hsCRP, high-sensitivity C-reactive protein.
red-O, trichrome staining, and 3,3Ј-diaminobenzidine-chromogenic detection of immunoglobulins was performed in human lesions fixed in 4% paraformaldehyde as described previously. 8, 15, 16 
Affinity Purification of Immunoglobulins
Proteins that bind to 3-nitrotyrosine were affinity isolated using an Amino Link Plus Immobilization Kit (Pierce Biotechnology, Inc, Rockford, IL), as described previously with minor modifications. 8 Briefly, 10 mg plasma proteins (combining plasma from 3 patients with CAD) were diluted in binding buffer (50 mmol/L potassium phosphate, 400 mmol/L NaCl, pH 7.5), applied to the column, and incubated for 1 hour at room temperature. Unbound protein fractions were eluted by centrifugation with binding buffer. Bound proteins were eluted with 0.1 mol/L citrate, pH 2.5, and neutralized with 1 mol/L Tris, pH 9. Bound fractions were concentrated and buffer exchanged using Millipore 10-kDa centrifugal filter units (Millipore Corporation, Billerica, MA). The protein fractions were separated on 10% SDS-PAGE and transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore Corporation, Bedford, MA), at 100 V and 4°C. After blocking with 3% BSA in Tris buffered saline with 0.05% tween-20, the membranes were incubated with either goat antihuman immunoglobulin G (IgG)-IRDye 800 CW (Rockland Immunochemicals, Inc, Boyertown, PA) or mouse antihuman IgM (1:2500; Sigma, St. Louis, MO) plus goat antimouse IgG conjugated to Alexa Fluor 680 (1:5000; Invitrogen, Eugene, OR) in blocking buffer. Images were obtained with an Odyssey near-infrared imaging system (LI-COR, Inc, Lincoln, NE) at 700 nm and 800 nm.
Human arterial tissue was obtained from the National Disease Resource Institute (Philadelphia, PA) or the Cleveland Clinic. Tissues (approximately 1 g) were cleaned of connective tissue and blood, snap-frozen in liquid nitrogen, and pulverized in the frozen state and stored at Ϫ80°C until use. Frozen tissue powder was thawed in 5 mL extraction buffer containing a protease inhibitor cocktail (Sigma, St. Louis, MO), and macerated further with a Tissue-Tek (Cincinnati, OH) homogenizer operated on full power for 10 s. This procedure was repeated 4 times per tissue sample. Tissue extracts were centrifuged at 700 g for 5 minutes and 21 000 g twice for 10 minutes to remove particulate material. Supernatants were combined and loaded to appropriate columns for affinity enrichment.
Isotype Determination
ELISA methodologies were developed to determine the isotype and the subisotype of the circulating immunoglobulin that recognize protein-bound 3-nitrotyrosine. First, to differentiate between IgG and IgM, 100 L of 10 g/mL of the synthetic 3-nitrotyrosine octapeptide described earlier was diluted in 50 mmol/L bicarbonate buffer, pH 9, and added in the wells of 96 well plates (MAXI-SORP, Nunc, Roskilde, Denmark). After overnight incubation at 4°C, the plates were washed and incubated in the presence of 100 L/well 3% BSA in Tris buffered saline with 0.05% tween-20 (working buffer) for 2 hours at room temperature. Human plasma from patients with CAD (5 mg plasma protein/mL) were added to each well and incubated for 2 hours at room temperature. Antihuman IgG and antihuman IgM HRP-conjugated antibodies (Sigma) diluted to 1:5000 in working buffer were added to appropriate series of wells. Peroxidase activity bound to each well was determined with 3,3Ј,5,5Ј tetramethylbenzidine (Pierce) substrate.
To determine the IgG subclass of the antibody, microplates were coated with 100 L of 5 g/mL solution of nitrated and native ceruloplasmin, fibronectin, and fibrinogen. The plates were incubated overnight at 4°C. After blocking, 100 L human plasma (diluted 1:40), alone or in the presence of 10 mol/L synthetic 3-nitrotyrosine octapeptide (specificity control) in blocking buffer, was added to each well and incubated for 1 hour, followed by the addition of 100 L/well 1:2000 dilutions of monoclonal HRPconjugated antihuman IgG 1, 2, 3, and 4 (Sigma). Absorbance was measured at 450 nm on a microplate reader (Spectra-Max 250; Molecular Devices Corporation, Sunnyvale, CA). The background absorbance obtained with unmodified proteins was subtracted from the absorbance of the samples that reacted with the nitrated protein antigens.
Ligand Competition ELISA
A competition ELISA described previously was implemented to determine the levels and specificity of circulating immunoglobulins that recognize 3-nitrotyrosine in human plasma. 10 Briefly, each well of a 96-well microtiter plate (MAXI-SORP) was coated with 50 L of serial dilutions of human plasma (0.02-10 mg protein/mL) in 50 mmol/L sodium bicarbonate buffer, pH 9. After blocking, 75 nmol/L HRP-conjugated 3-nitrotyrosine or an HRP-conjugated synthetic octapeptide containing 2 3-nitrotyrosine residues (CGni-troYGGGnitroYG) were added in 0.1% BSA in Tris buffered saline with 0.05% tween-20 and were incubated for 1 hour. Peroxidase activity bound to each well was determined using the H 2 O 2peroxidase-mediated oxidation of tetramethylbenzidine measuring absorbance at 450 nm. To test the specificity of detection, the absorbance at 450 nm was competed in each sample by including excess free, unlabeled 3-nitrotyrosine (2.5 mmol/L). In some experiments, the CGnitroYGGGnitroYG octapeptide was used as the competitor.
A polyclonal rabbit antinitrotyrosine IgG antibody (0.08 -40 g protein/mL), characterized in detail previously, 15, 16 was run each day along with plasma samples. The antibody titer in each sample was calculated using the absorbance at 450 nm of the samples (Abs 450 nm ), and the average of the parameters of the dose-response curve obtained with the polyclonal antinitrotyrosine antibody using the following equation:
where 200 represents the sample dilution, and the average values for the parameters A, B, C, and D were 0.07, 2.21, 0.04, and 1.57, respectively, denoting minimal absorbance, slope at the linear part of the curve, the dose at the central point, and the maximal absorbance, respectively. Antibody titers in human plasma are therefore expressed as microgram equivalents of the polyclonal antibody per milliliter of plasma (g Ab Eq/mL plasma).
Isolation of Nitrated Proteins for Mass Spectrometry
Proteins bearing the 3-nitrotyrosine epitope were affinity captured from human CAD plasma by using the polyclonal anti-3nitrotyrosine antibody conjugated to a recombinant protein A column (Pierce). Pooled plasma from 6 patients with CAD (14 mg total protein) was loaded into the column in 0.1 mol/L HEPES, pH 7.4 (binding buffer), and was incubated overnight at 4°C. The column was washed successively with 10 mL of the following solutions: binding buffer, 0.5 mol/L NaCl, and binding buffer again. Bound fractions were eluted with 10 mL of 0.1 mol/L glycine, pH 2.5, containing 0.15 mol/L NaCl. After concentration and buffer exchange using Centriprep YM-10 filters (Millipore Corporation, Billerica, MA), proteins were separated on 10% SDS-PAGE, and stained with colloidal blue (Invitrogen, Carlsbad, CA). An identical gel was transferred to the polyvinylidene difluoride membrane for immunodetection of protein 3-nitrotyrosine using the polyclonal antinitrotyrosine antibody.
Gel-Liquid Chromatography Tandem Mass Spectrometry Analysis
Colloidal blue-stained gels were cut into 11ϫ2-mm slices and in-gel digested with trypsin as described previously. 8 Tryptic peptide digests were analyzed by an LTQ linear ion trap mass spectrometer (Thermo Electron, San Jose, CA) coupled to an Eksigent 2-dimensional liquid chromatography system (Eksigent Technologies, Livermore, CA) and autosampler. Buffers A and B were 0.1% formic acid/1% methanol and 80% acetonitrile/0.1% formic acid/1% methanol, respectively. Peptides were loaded isocratically onto a C18 trap column (75 m IDϫ25 mm; New Objective Proteopep 2 [New Objective, Inc., Woburn, MA]) at a flow rate of 1 L/min in 2% B. Peptides were then eluted onto a C18 analytic column (75 m IDϫ150 mm; New Objective Proteopep 2). A linear gradient was then initiated at a flow rate of 300 nL/min for 90 minutes from 3% to 40% B. The mass spectrometer was set to scan m/z repetitively from 375 nm to 1600 nm followed by data-dependent tandem mass spectrometry scans on the 5 most abundant ions with dynamic exclusion enabled.
Generation and Evaluation of SEQUEST Peptide Assignments
DTA files were generated from the tandem mass spectrometry spectra extracted from RAW data files (intensity threshold, 1000; minimum ion count, 50) and processed by the ZSA and Correction algorithms of the SEQUEST Browser program. DTA files were submitted to Sorcerer-SEQUEST (ver. 3.11, rev 11; Sagen Research, San Jose, CA) using the following parameters: Database searching was performed against a Uniprot database containing Homo sapiens sequences from Swiss-Prot plus common contaminants, which were then reversed and appended to the forward sequences (91 522 entries). The database was indexed with the following parameters: mass range of 600 to 3500 atomic mass units, tryptic cleavages with a maximum of 1 missed cleavage, and static modifications of cysteine by carboxyamidomethylation (ϩ57 amu). The DTA files were searched with a 2.0-amu peptide mass tolerance, 1.0-amu fragment ion mass tolerance, and variable modification of methionine (ϩ16 amu). Potential sequence-to-spectrum peptide assignments generated by Sorcerer-SEQUEST were loaded into Scaffold (version 2.2; Proteome Software, Portland, OR) to validate protein identifications and perform manual inspection of tandem mass spectrometry spectra containing 3-nitrotyrosine. Protein identifications were accepted at a threshold of Ն99% protein confidence with Ն2 unique peptides at Ն80% confidence. From these proteins, manual inspection of 3-nitrotyrosine-containing tandem mass spectrometry spectra were performed using the following criteria: (1) assignment of the majority of fragment ion abundance, (2) 3-nitrotyrosine (ϩ45 amu) modification supported by either y-or b-ions series (Ն5 consecutive fragments), and (3) correctly assigned charge state and diagnostic markers, such as N-terminal proline, C-terminal aliphatic amino acids, and loss of H 2 O/ammonia consistent with amino acid sequence.
Statistical Analysis
The Student t test or Wilcoxon rank-sum test for continuous variables and 2 test for categorical variables were used to examine the difference between the groups (CAD versus non-CAD). The relationship between plasma immunoglobulin levels and risk for having CAD was determined by calculating the odds ratio and 95% confidence intervals using multiple logistic regression treating immunoglobulin levels against protein-bound nitrotyrosine as a continuous variable. Models adjusted for traditional risk factors (age, gender, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, smoking) or traditional risk factors plus history of myocardial infarction, and medications (aspirin, angiotensin-converting enzyme, statin, ␤-blockers). Cubic spline curves with 95% confidence intervals were constructed to illustrate the relationship between antinitrotyrosine immunoglobulin levels and the odds ratio of angiographic evidence of significant CAD. All analyses were performed using R 2.13.1 (Foundation for Statistical Computing, Vienna, Austria), and probability values Ͻ0.05 were considered statistically significant.
Results
Nitrated Proteins in Human Atherosclerotic Lesions and Plasma
The presence of nitrated proteins in atherosclerotic lesions or plasma of patients with CAD could serve as neo-epitopes, triggering an immune response and the elaboration of immunoglobulins. Therefore, we first sought to document the presence of nitrated proteins by immunohistochemistry in human lesions and by mass spectrometry in lesion extracts as well as plasma of subjects with CAD.
A typical atherosclerotic lesion in human carotid artery stained with Oil red-O is depicted in Figure 1A and 1B. The immunofluorescence images after staining for nitrated protein epitopes is depicted in Figure 1C through 1E, and indicate the presence of nitrated proteins within the lesion, consistent with previous studies in human atherosclerotic lesions. 6 The specificity of the antinitrotyrosine antibodies used for staining was confirmed by competition experiments with excess of the nitrated octapeptide (CGnitroYGGGnitroYG) ( Figure 1D ). Moreover, staining with antihuman IgG also revealed the presence of 3-nitrotyrosine octapeptide was used to bind the immunoglobulins and the respective antihuman immunoglobulin to develop, we quantified the relative levels of IgG and IgM in the plasma of subjects with CAD. Plasma immunoglobulins that recognize the nitrotyrosine modification were predominantly IgG, because the signal was nearly 5-fold higher for IgG than IgM (1.4Ϯ0.3 and 0.3Ϯ0.3 average absorbance respectively, Figure 3A) . Therefore, subsequent studies focused on quantifying the levels of circulating IgG immunoglobulin isoform in subjects. The IgG present in human plasma of subjects with CAD was characterized further by isotyping using an ELISA in which potential endogenous 3-nitrotyrosine-containing proteins-nitrated ceruloplasmin, nitrated fibronectin, and nitrated fibrinogen-were used as antigens. The predominant isotype that recognized preferentially the nitrated proteins was IgG2 ( Figure 3B ).
ELISA Development to Quantify Plasma Levels of Antinitrotyrosine Immunoglobulins in Subjects With and Without CAD
We next sought to determine whether plasma immunoglobulins that recognize the neo-epitope 3-nitrotyrosine are more prevalent in subjects with CAD. For these studies, we modified a competition ELISA described previously for use in human plasma and mouse models of atherosclerosis. 8, 10 Typical antigen-antibody binding curves using the nitrotyrosine-containing octapeptide conjugated to HRP are shown in Figure 3C . No binding was observed using the same tyrosine-containing octapeptide. The specificity of binding was confirmed by competing the binding of the 3-nitrotyrosine peptide-conjugated HRP with excess free 3-nitrotyrosine (2.5 mmol/L), as well as unconjugated nitrotyrosine peptide (75 mol/L). In all subsequent analyses, the difference between the absorbance in the absence versus presence of excess 3-nitrotyrosine (2.5 mmol/L), considered as background, was used to calculate the titer of circulating anti-3nitrotyrosine immunoglobulins. Furthermore, the binding of immunoglobulins to the HRP-conjugated nitrotyrosine peptide was competed by a peptide derived from apoA-I ( 213 LAEnitro YHAK 219 ) containing 3-nitrotyrosine in place of tyrosine in position 216. Maximal inhibition was obtained at 1 mol/L 213 LAEnitroYHAK 219 (Figure 3D ). At the same concentration, the unmodified apoA-I peptide, 213 LAEYHAK 219 , was unable to compete ( Figure 3D ), confirming the specificity of the immunoglobulins toward protein tyrosine-nitrated epitopes.
Plasma Levels of Antibodies That Recognize Protein Nitrotyrosine Are Increased in Subjects With CAD
Plasma levels of anti-3-nitrotyrosine immunoglobulins were quantified in subjects with and without CAD as documented during elective cardiac evaluations, as described in Methods. Subjects with clinically documented CAD had 10 times higher levels of anti-3-nitrotyrosine immunoglobulins (3.75Ϯ1.8 g Ab Eq/mL plasma) than subjects without CAD (0.36Ϯ0.8 g Eq/mL plasma; PϽ0.001 for comparison with CAD) ( Figure 4A ). Interestingly, subjects with angiographic evidence of significantly obstructed (Ն50% stenosis) CAD showed increased plasma anti-3-nitrotyrosine immunoglobulin titers compared with subjects without CAD, regardless of the number of coronary arteries affected by CAD ( Figure 4B) . A striking dose-dependent positive association was observed between plasma levels of antinitrotyrosine IgG and angiographic evidence of significant CAD; in fact, because the non-CAD cohort had low levels of anti-3-nitrotyrosine immunoglobulins (undetectable in 76% of the samples), a remarkably large odds ratio was observed for anti-3nitrotyrosine IgG titer versus the presence of significant angiographic evidence of CAD ( Figure 4C ). Multilogistic regression analyses indicated that the robust association of immunoglobulin levels against protein 3-nitrotyrosine with cardiovascular risk remains significant even after adjustments for multiple traditional risk factors, including age, gender, systolic blood pressure, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, smoking, history of myocardial infarction, and medications (aspirin, angiotensinconverting enzyme inhibitors, statin, ␤-blockers; Table 2 ).
Discussion
Clinical evidence and data from animal models have indentified various forms of oxidized lipoproteins and heat shock proteins as immunogens that induce adaptive immune responses, including antibody elaboration, and that modulate atherosclerotic lesion formation in experimental models of atherosclerosis. 20 -29 Most studies have focused predominantly on covalent adducts formed by the addition of electrophilic lipid peroxidation products to proteins and their relationship to the development and progression of atherosclerosis. 20 -26 Moreover, the levels of circulating IgM that recognized oxidized forms of low-density lipoprotein with covalently adducted lipid oxidation products have been reported to correlate with severity of atherosclerosis in mouse models and in some studies with the progression of atherosclerosis in coronary or carotid vascular beds, or with risk for myocardial infarction and death in humans. 25 Collectively, these data highlight the critical importance of understanding the immune system responses in CAD and raise the possibility of novel therapeutic treatments for atherosclerosis. 30, 31 The data also underscore the need for identifying antigens and immune responses that are linked mechanistically to the underlying pathophysiology of cardiovascular diseases.
Protein tyrosine nitration is considered to be a posttranslational modification reflective of inflammatory-mediated oxidative processes involving nitric oxide-derived oxidants. Although the ability of nitrated proteins to induce the generation of specific antibodies in experimental animals has long been known, 15, 16, [32] [33] [34] [35] [36] the contribution of this posttranslational protein modification as a trigger of immune reactions in pathology has just recently been explored. 10 -12 In this study we demonstrated for the first time the association of CAD, the most common and life-threatening cardiovascular condition, with increased plasma levels of immunoglobulins reactive against proteins modified by nitration. The binding of plasma immunoglobulins to target 3-nitrotyrosine-containing bait (HRP conjugated to 3-nitrotyrosine or 3-nitrotyrosine containing octapeptide) served as a competition-based ELISA to quantify autoantibody titers for 3-nitrotyrosine-recognizing immunoglobulins within subjects' plasma. The specificity of the methodology was confirmed by numerous approaches, including demonstration that the 3-nitrotyrosine binding activity in plasma was outcompeted specifically by free 3-nitrotyrosine as well as by 3-nitrotyrosine-modified peptides and proteins, ruling out nonspecific binding. In particular, a nitrated peptide reflecting an endogenous nitrated tyrosine residue identified in apoA-I recovered from human atherosclerotic plaque, 7 but not the native tyrosine-containing peptide, was able to outcompete the binding of the 3-nitrotyrosine-coupled HRP bait to immunoglobulins. Moreover, the circulating immunoglobulins were able to recognize nitrated fibrinogen and other nitrated plasma proteins but not the native counterparts ( Figure 3B ). These data support a possible specific antigenic role of those endogenous-nitrated proteins as the neo-epitope that triggers antinitrotyrosine immunoglobulins. It is remarkable that both of these proteins (apoA-I and fibrinogen) have been reported previously to be nitrated selectively in plasma from patients with CAD relative to healthy control subjects, and that nitration of these particular proteins may have a potential functional role in cardiovascular events. In the case of fibrinogen, nitration increases the rate as well as the extent of fibrin clot formation, 17, 18 leading potentially to enhanced thrombotic risk and adverse cardiovascular events. On the other hand, 3-nitrotyrosine-modified apoA-I was found in serum and human atherosclerotic lesions. Furthermore, exposure of apoA-I to myeloperoxidase, an enzymatic source of nitric oxide-derived oxidants, creates a dysfunctional form of highdensity lipoprotein with diminished ATP-binding cassette sub-family A1-dependent cholesterol efflux capacity and reduced lecithin cholesterol acyl transferase activity. 7, 37 The molecular mechanisms for the production of immunoglobulins with specific and selective epitope recognition for 3-nitrotyrosine have been explored in mouse models. 35, 36 Termination of self-tolerance and escaping of negative selection after active immunization with nitrated peptides was documented. 35, 38 Moreover, monoclonal antibodies that recognize only nitrated ␣-synuclein (including stereospecific clones that recognized 1 of the 4 nitrated tyrosine residues in ␣-synuclein) but not the unmodified protein or other tyrosinenitrated proteins, 32 as well as antibodies recognizing only nitrated Mn superoxide dismutase 33 and only nitrated tau 34 have been reported. In one model of mouse neurodegeneration, the specific immune response to nitrated ␣-synuclein produced a vigorous immunoinflammatory response that led to the degeneration of dopamine-producing neurons. 39 The pathophysiological relevance of circulating immunoglobulins targeting protein 3-nitrotyrosine remains to be determined. Indeed, despite the strikingly elevated levels of anti-3-nitrotyrosine antibodies in subjects with CAD, it is possible that the antibody response within atherosclerotic plaque may promote a protective role, with immunoglobulins targeting proteins bearing potentially threatening modifications for destruction. Furthermore, the relatively high-risk cohort of subjects examined (those undergoing elective diagnostic cardiac evaluations) makes the results of the current study of unclear relevance when translated to a communitybased screen. It also remains to be determined whether elevated levels of 3-nitrotyrosine-targeted antibodies are increased in subjects prior to clinically overt development of atherosclerotic CAD, and whether increased levels may serve as a sentinel of increased risk of major adverse cardiac events. Further studies are needed to both identify the role, if any, of 3-nitrotyrosine immunoglobulins in CAD pathophysiology, as well as whether anti-3-nitrotyrosine immunoglobulin titer carries prognostic value and is modulated by CAD-targeting therapies. Affinity enrichment for nitrated proteins from human CAD plasma. Pooled plasma CAD subjects was applied to a agarose column that a polyclonal anti-nitrotyrosine antibody was ligated. After binding and extensive washing the bound proteins were eluted with 0.1 M glycine, pH 2.5, containing 0.15 M NaCl and separated in 10% SDS-PAGE. (A) Colloidal blue stain and (B) western blot developed with an anti-nitrotyrosine polyclonal antibody. Lanes 1, and 4, un-fractionated plasma (input); Lanes 2, and 5, last wash before elution; Lanes 3, and 6, eluted bound proteins.
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